Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.20 -0.18 (-4.21%)
At close: Aug 20, 2026 · 1:43 PM UTC

Apimeds Pharmaceuticals US (APUS) Current Leases (2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Current Leases came in at $39578.0 in Q4 2025.

Apimeds Pharmaceuticals US (APUS) Current Leases (2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 1 years of Current Leases data on file, last reported at $39578.0 in Q4 2025.

  • Quarterly Current Leases changed N/A year-over-year to $39578.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $39578.0 (changed N/A YoY) and the FY2025 annual result came in at $39578.0, changed N/A from the prior year.
  • Current Leases was little changed at $39578.0 in Q4 2025.
  • In the past five years, Current Leases ranged from a high of $39578.0 in Q4 2025 to a low of $39578.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Haleon 43.89 Bn 42.93 Bn - -
2 Teva Pharmaceutical Industries 43.01 Bn 39.35 Bn 2.15 Bn -
3 Zoetis 31.52 Bn 29.84 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.61 Bn 22.81 Bn 5.10 Bn -
5 United Therapeutics 22.17 Bn 19.51 Bn 683.80 Mn -
6 Viatris 18.73 Bn 17.85 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.51 Bn 15.12 Bn 935.80 Mn -
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.12 Bn 9.96 Bn - -
10 Apimeds Pharmaceuticals US 7.20 Mn 7.20 Mn - 59,523.00

Historic Data

Download Data
DateValue
Dec 31, 2025 39,578.00